6,7-unsaturated-7-carbamoyl substituted morphinan derivative

Details 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 6,7-unsaturated-7-carbamoyl substituted morphinan derivative

2006-05-25

2011-12-27

Seaman, D M (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S046000

Reexamination Certificate

active

08084460

ABSTRACT:
A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation.A compound represented by the formula (I):wherein R1and R2are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4is hydrogen or lower alkyl, R5is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl,or a pharmaceutically acceptably salt, or a solvate thereof is provided.

REFERENCES:
patent: 4272541 (1981-06-01), Kotick et al.
patent: 4275205 (1981-06-01), Kotick et al.
patent: 4347361 (1982-08-01), Quick et al.
patent: 4370333 (1983-01-01), Ghosh et al.
patent: 4440932 (1984-04-01), Kotick et al.
patent: 4443605 (1984-04-01), Kotick et al.
patent: 6177438 (2001-01-01), Nagase et al.
patent: 2004/0019071 (2004-01-01), Sakami et al.
patent: 2004/0024004 (2004-02-01), Sherman et al.
patent: 2004/0157784 (2004-08-01), Chopdekar et al.
patent: 2005/0038061 (2005-02-01), Schutz et al.
patent: 2006/0052409 (2006-03-01), Kawai et al.
patent: 1 522 542 (2005-04-01), None
patent: 56-15290 (1981-02-01), None
patent: 58-8067 (1983-01-01), None
patent: 2000/503019 (2000-03-01), None
patent: 2003/528819 (2003-09-01), None
patent: 2004-501094 (2004-01-01), None
patent: 2004/522706 (2004-07-01), None
patent: 2006/502190 (2006-01-01), None
patent: WO 95/13071 (1995-05-01), None
patent: WO 97/25331 (1997-07-01), None
patent: WO 01/37785 (2001-05-01), None
patent: WO 01/37785 (2001-05-01), None
patent: WO 01/37785 (2001-05-01), None
patent: WO 01/85150 (2001-11-01), None
patent: WO 01/85150 (2001-11-01), None
patent: WO 01/85257 (2001-11-01), None
patent: WO 01/85257 (2001-11-01), None
patent: WO 02/36573 (2002-05-01), None
patent: WO 02/42309 (2002-05-01), None
patent: WO 2004/005294 (2004-01-01), None
patent: WO 2004/007503 (2004-01-01), None
patent: WO 2004/026819 (2004-04-01), None
patent: WO 2005/105093 (2005-11-01), None
patent: WO 2005/105093 (2005-11-01), None
patent: WO 2005/117589 (2005-12-01), None
patent: WO 2006/034039 (2006-03-01), None
patent: WO 2006/034309 (2006-03-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Chun-Su et al., The journal of Supportive Oncology, vol. 2(2), pp. 11-122, ( 2004 ).
Ohkawa et al.; “7-Arylidenenaltrexones as Selective δ1Opioid Receptor Antagonists”, J. Med. Chem., vol. 41, pp. 4177-4180, (1998).
Fujii et al.; “The First Example of the Steroselective Synthesis of 7β-Carbamoyl-4,5α-Epdxymorphinan Via a Novel and Reactive γ-Lactone”, Chem. Pharm. Bull., vol. 52, No. 6, pp. 747-750, (2004).
Leland et al.; “Analgesic Narcotic Antagonists. 5. 7,7-Dimethyldihydrocodeinones and 7,7-Dimethyldihydromorphinones1”, J. Med. Chem., American Chemical Society, vol. 24, pp. 717-721, (1981).
Kotick et al.; “Analgesic Narcotic Antagonists. 8. 7α-Alkyl-4,5α-Epoxymorphinan-6-Ones”, J. Med. Chem., American Chemical Society, vol. 24, pp. 1445-1450, (1981).
Herlihy et al.; “Novel Opiates and Antagonists. 5. 7-Carbethoxy-N-(Cycloalkylmethyl)-3-Hydroxymorphinan-6-Ones and -Isomorphinan-6-Ones”, American Chemical Society, J. Med. Chem., vol. 25, pp. 986-990, (1982).
Kotick et al.; “Analgesic Narcotic Antagonists. 15. Potent Narcotic Agonist 7β-(Arylalkyl)-4,5α-Epdxymorphinans”, J. Med. Chem., American Chemical Society, vol. 26, pp. 1050-1056, (1983).
Koolpe et al.; “Opioid Agonists and Antagonists. 6-Desoxy-6-Substituted Lactone, Epoxide, and Glycidate Ester Derivatives of Naltrexone and Oxymorphone”, J. Med. Chem., American Chemical Society, vol. 28, pp. 949-957, (1985).
Hernãndez-Gallegos et al.; “A Free-Wilson/Fujita-Ban Analysis and Prediction of the Analgesic Potency of Some 3-Hydroxy- and 3-Methoxy-N-Alkylmorphinan-6-One Opioids1”, J. Med. Chem., American Chemical Society, vol. 33, pp. 2813-2817, (1990).
Portoghese et al.; “Synthesis of Naltrexone-Derived δ-Opioid Antagonists. Role of Conformation of the δ Address Moiety”, J. Med. Chem., American Chemical Society, vol. 37, pp. 579-585, (1994).
Gao et al.; “Synthesis of 7-Arylmorphinans. Probing the “Address” Requirements for Selectivity at Opioid δ Receptors”, J. Med. Chem., American Chemical Society, vol. 41, pp. 3091-3098, (1998).
Ananthan et al.; “Synthesis, Opioid Receptor Binding, and Biological Activities of Naltrexone-Derived Pyrido- and Pyrimidomorphinans”, J. Med. Chem., American Chemical Society, vol. 42, pp. 3527-3538, (1999).
Nagase et al.; “Facile Intramolecular O-14 → C-7 Acetyl Transfer in Opiate 14-Acetate Esters”, J. Org. Chem., American Chemical Society, vol. 55, pp. 365-367, (1990).
Leland et al.; “7α- Or 7β-(4-Phenylbutyl)Dihydrocodeine Derivatives”, J. Org. Chem., American Chemical Society, vol. 48, pp. 1813-1819, (1983).
Gao et al.; “Monophenylation of Morphinan-6-Ones With Diphenyliodonium Iodide”, J. Org. Chem., American Chemical Society, vol. 60, pp. 2276-2278, (1995).
Gao et al.; “Boron Tribromide-Catalyzed Rearrangement of 7,7-Diphenylhydromorphone to 6,7-Diphenylmorphine: A Novel Conversion of Ketones to Allylic Alcohols”, J. Org. Chem., American Chemical Society, vol. 61, pp. 2466-2469, (1996).
Brandt; “A Uniform Molecular Model of δ Opioid Agonist and Antagonist Pharmacophore Conformations”, Journal of Computer-Aided Molecular Design, Vo. 12, pp. 615-621, (1998).
Ronzoni et al.; “Synthesis and NMR Characterization of a Novel Class of Thienomorphinans”, Organic Letters, vol. 1, No. 3, pp. 513-515, (1999).
Lester et al.; “Vilsmeier Reactions With 14-Hydroxy-Dihydrocodeinone and Derived Enol Ethers”, Tetrahedron, vol. 20, pp. 1407-1417, (1964).
Lester et al.; “Vilsmeier Reactions With Cyclic Ketals of 14-Hydroxy-dihydrocodeinone and Some New Cyclic Derivatives of 14-Hydroxy-dihydrocodeinone ”, Tetrahedron, vol. 21, pp. 771-778, (1965).
Boche et al.; “Electrophilic Amination of Acyl Anion Equivalents: Mild Oxidation of Aldehydes to Amides Via 0-(Trimethylsilyl)Aldehyde Cyanohydrin Anions”, Tetrahedron Letters, vol. 23, No. 32, pp. 3255-3256, (1982).
“Persistently Low Natural Killer Cell Activity”, Life Science, vol. 48, No. 2, pp. 111-116, (1991).
Munson et al.; “Ligand: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems”, Analytical Biochemistry, vol. 107(1), pp. 220-239, (1980).
Dalzell et al.; “4,5-Alpha-Epoxy-3-Hydroxy-7,17-DI:Substd.-Morphinan-6-One(S)—Useful as Analgesics and/or Narcotic”, Abstract, JP 57-122088, Jul. 29, 1982.
Portoghese, “The Role of Concepts in Structure-Activity Relationship Studies of Opiod Ligands,” J. Med. Chem., 35(11):1927-1937 (1992).
International Search Report mailed Jun. 20, 2006, for Application No. PCT/JP2006/310454.
International Preliminary Report on Patentability issued Nov. 29, 2007, for Application No. PCT/JP2006/310454.
Supplementary European Search Report mailed Jul. 11, 2011, in European Application No. EP 06746833.0.

Affiliated with

Also associated with

Rating

6,7-unsaturated-7-carbamoyl substituted morphinan derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 6,7-unsaturated-7-carbamoyl substituted morphinan derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6,7-unsaturated-7-carbamoyl substituted morphinan derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4305105